We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. ADC Therapeutics SA (ADCT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ADC Therapeutics SA is one of 947 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 15% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ADCT has returned about 99.5% since the start of the calendar year. At the same time, Medical stocks have gained an average of 6.2%. This means that ADC Therapeutics SA is performing better than its sector in terms of year-to-date returns.
Catalyst Pharmaceutical (CPRX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 15.9%.
For Catalyst Pharmaceutical, the consensus EPS estimate for the current year has increased 8.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ADC Therapeutics SA belongs to the Medical - Biomedical and Genetics industry, a group that includes 465 individual stocks and currently sits at #89 in the Zacks Industry Rank. This group has gained an average of 18.4% so far this year, so ADCT is performing better in this area.
On the other hand, Catalyst Pharmaceutical belongs to the Medical - Drugs industry. This 146-stock industry is currently ranked #78. The industry has moved +6% year to date.
Investors with an interest in Medical stocks should continue to track ADC Therapeutics SA and Catalyst Pharmaceutical. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. ADC Therapeutics SA (ADCT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ADC Therapeutics SA is one of 947 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 15% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ADCT has returned about 99.5% since the start of the calendar year. At the same time, Medical stocks have gained an average of 6.2%. This means that ADC Therapeutics SA is performing better than its sector in terms of year-to-date returns.
Catalyst Pharmaceutical (CPRX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 15.9%.
For Catalyst Pharmaceutical, the consensus EPS estimate for the current year has increased 8.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ADC Therapeutics SA belongs to the Medical - Biomedical and Genetics industry, a group that includes 465 individual stocks and currently sits at #89 in the Zacks Industry Rank. This group has gained an average of 18.4% so far this year, so ADCT is performing better in this area.
On the other hand, Catalyst Pharmaceutical belongs to the Medical - Drugs industry. This 146-stock industry is currently ranked #78. The industry has moved +6% year to date.
Investors with an interest in Medical stocks should continue to track ADC Therapeutics SA and Catalyst Pharmaceutical. These stocks will be looking to continue their solid performance.